Cannabis Sector Sees Investments and Competition, Psychedelic Sector Focuses on Research and IP

Organigram expanded its investment in Phylos Bioscience, securing priority access to advanced genetics and a robust seed pipeline through 2030. The company also walked away from a deal with The Cannabist as a competing offer emerged, while Cannara Biotech claimed top market share in Québec following a strong vape launch. In the psychedelic sector, AtaiBeckley completed US redomiciliation, Cybin announced $100 million ATM financing, Enveric Biosciences strengthened its IP portfolio, and GH Research will give an update on FDA IND progress for its lead depression therapy.